MedTech Dive January 22, 2026
AdvaMed CEO Scott Whitaker and Mick Farrell, new board chair of the trade group, weighed in on important issues for the medtech industry one year into the Trump administration.
One year into the second Trump administration, leaders of the medtech industry’s largest lobbying group provided updates on key policy initiatives. AdvaMed CEO Scott Whitaker fielded questions on tariffs, which remain a question looming over the medical device sector, and shared more details on user fee negotiations in a Wednesday press conference.
Resmed CEO Mick Farrell, who became board chair of AdvaMed earlier this month, also discussed his priorities and recent digital health policies from the Food and Drug Administration.
AdvaMed wants tariff certainty
Medtech companies are seeking stability after...
Today's Sponsors
Today's Sponsor